Aclaris Therapeutics (ACRS) Reaches $25.82 Formed H&S; Last Week Sasol Limited (ADR) (SSL) Analysts

August 25, 2017 - By Nellie Frank

Among 7 analysts covering Sasol (NYSE:SSL), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Sasol had 10 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of Sasol Limited (ADR) (NYSE:SSL) has “Hold” rating given on Tuesday, July 18 by J.P. Morgan. On Tuesday, April 5 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. Morgan Stanley upgraded the stock to “Overweight” rating in Wednesday, August 10 report. The rating was downgraded by JP Morgan on Tuesday, July 18 to “Neutral”. The rating was downgraded by Macquarie Research on Wednesday, March 9 to “Neutral”. The firm has “Buy” rating given on Tuesday, August 16 by Bank of America. Credit Suisse initiated the shares of SSL in report on Monday, September 26 with “Outperform” rating. The company was upgraded on Wednesday, September 14 by Citigroup. The stock of Sasol Limited (ADR) (NYSE:SSL) has “Neutral” rating given on Friday, March 11 by Bank of America. The stock has “Buy” rating by Citigroup on Wednesday, September 9. See Sasol Limited (ADR) (NYSE:SSL) latest ratings:

18/07/2017 Broker: J.P. Morgan Rating: Hold Downgrade
18/07/2017 Broker: JP Morgan Old Rating: Overweight New Rating: Neutral Downgrade

Aclaris Therapeutics Inc (ACRS) formed H&S with $24.27 target or 6.00% below today’s $25.82 share price. Aclaris Therapeutics Inc (ACRS) has $774.51 million valuation. The stock increased 0.43% or $0.11 during the last trading session, reaching $25.82. About shares traded. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 25.57% since August 25, 2016 and is uptrending. It has outperformed by 8.87% the S&P500.

Sasol Limited is an international integrated chemicals and energy company. The company has market cap of $19.34 billion. The Firm develops and commercializes technologies, and manufactures and operates facilities to produce a range of product streams, including liquid fuels, chemicals and low-carbon electricity. It has a 11.69 P/E ratio. The Company’s operating business units include Mining and, Exploration and Production International.

The stock decreased 0.47% or $0.14 on August 24, reaching $29.55. About shares traded. Sasol Limited (ADR) (NYSE:SSL) has risen 6.49% since August 25, 2016 and is uptrending. It has underperformed by 10.21% the S&P500.

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 12 analyst reports since November 2, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $3600 target in Monday, June 26 report. Leerink Swann initiated Aclaris Therapeutics Inc (NASDAQ:ACRS) rating on Tuesday, November 29. Leerink Swann has “Outperform” rating and $54 target. Citigroup initiated Aclaris Therapeutics Inc (NASDAQ:ACRS) on Monday, November 2 with “Buy” rating. The rating was initiated by Guggenheim with “Buy” on Friday, June 10. The rating was initiated by Jefferies with “Buy” on Monday, November 2. The rating was maintained by Jefferies with “Buy” on Monday, September 19. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) earned “Market Perform” rating by JMP Securities on Friday, September 30. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) has “Buy” rating given on Friday, July 28 by Jefferies. Jefferies maintained it with “Buy” rating and $23 target in Friday, August 12 report. On Wednesday, August 9 the stock rating was maintained by Cantor Fitzgerald with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com